TACE Survival Outcomes for Intermediate-Stage Hepatocellular Carcinoma
For patients with intermediate-stage hepatocellular carcinoma and preserved liver function (Child-Pugh A), transarterial chemoembolization (TACE) achieves 1-year survival rates of 90-97%, 2-year survival of 58-78%, and 3-year survival of 20-61%, with median overall survival ranging from 34-45 months.
Survival Data by Time Point
Short-Term Survival (1 Year)
- 1-year survival rates consistently exceed 90% in patients with preserved liver function (Child-Pugh score ≤7) 1, 2
- One study reported 97.1% 1-year survival using superselective DEBDOX TACE under cone-beam CT control 2
- Another cohort demonstrated 90.4% 1-year survival with conventional superselective TACE 1
Medium-Term Survival (2-3 Years)
Long-Term Survival
- Median overall survival of 33.9-45.2 months in well-selected patients 1, 2
- The median survival of 45.2 months was achieved in treatment-naïve patients with Child-Pugh score <7 1
Critical Prognostic Factors That Modify Survival
Negative Prognostic Indicators
The following factors significantly worsen survival outcomes 1:
- Age ≥75 years (hazard ratio for mortality increases)
- AFP ≥200 ng/mL at baseline
- Tumor number ≥11 (dramatically worse prognosis)
- Heterogeneous enhancement pattern on dynamic CT (indicates aggressive biology)
- Early tumor stage (T1-T2 vs T3-T4) is the strongest predictor after multivariate adjustment 3
Positive Prognostic Indicators
- Child-Pugh A liver function (essential for optimal outcomes) 1
- Single lobe involvement (better than bilobar disease) 3
- Younger age and lower BMI correlate with improved survival 3
Treatment Response Rates
TACE achieves exceptionally high objective response rates of 92-94% in appropriately selected patients 1, 2:
- Complete response: 42-63%
- Partial response: 29-58%
- Mean time to progression: 10.9 months 2
Liver Function Preservation During Repeated TACE
Liver function deterioration is modest with proper patient selection 1:
- After first TACE: 18.5% deterioration in Child-Pugh score, 12.3% in ALBI grade
- After second TACE: 15.6% deterioration in Child-Pugh score, 5.1% in ALBI grade
- After third TACE: 14.5% deterioration in Child-Pugh score, 11.1% in ALBI grade
This demonstrates that superselective TACE can be repeated safely without progressive hepatic decompensation in most patients 1.
Technical Factors Influencing Outcomes
Superselective catheterization under cone-beam CT guidance improves both safety and efficacy 2:
- Allows precise targeting of tumor-feeding vessels
- Minimizes non-target embolization
- Reduces major complication rates to 1.6% 2
Clinical Context and Guidelines
The Korean Liver Cancer Association (2023) emphasizes that TACE remains the standard of care for intermediate-stage HCC but requires careful patient selection based on tumor characteristics, liver function, and performance status 4. The decision to perform TACE should incorporate multidisciplinary input, with approximately 73% of hepatologists utilizing team approaches for patient selection 4.
TACE should be performed after evaluating: tumor stage, location, growth pattern, liver function (Child-Pugh score), performance status, vascular invasion status, and portal hypertension signs 4.
Common Pitfalls to Avoid
- Do not perform TACE in patients with Child-Pugh B/C cirrhosis unless tumors are very small and superselective technique is available 4
- Avoid TACE in patients with biliary obstruction or bilioenteric anastomosis due to high liver abscess risk 4
- Do not continue TACE indefinitely—approximately 60% of practitioners use scoring systems (BCLC B subclassification, HAP score, Up-to-seven criteria) to guide treatment decisions 4
- Ensure pre-treatment imaging is within 1 month of procedure, not exceeding 2 months 4